Armoda250 mg

Armoda is a wakefulness-promoting agent (the R-enantiomer of modafinil) used to improve wakefulness in adults with excessive sleepiness. Its established (FDA-approved) indications are:

• Narcolepsy - to reduce excessive daytime sleepiness.
• Obstructive sleep apnea (OSA) - as an adjunct to standard treatment (e.g., continuous positive airway pressure, CPAP) to improve wakefulness; Armoda does not treat the underlying airway obstruction and is not a substitute for CPAP or other primary OSA therapy.
• Shift work disorder (SWD) - to improve wakefulness in patients whose work schedule overlaps with the normal sleep period.

Armoda is sometimes used off-label for other causes of excessive sleepiness or fatigue (e.g., in certain psychiatric or neurological conditions); such use is not FDA-approved and should only be undertaken under specialist supervision.

Each tablet contains Armodafinil as the active ingredient, available in strengths such as 50 mg, 150 mg, and 250 mg, along with pharmaceutically acceptable excipients (e.g., diluents, binders, disintegrants, and lubricants) used in tablet formulation.

Armoda is a synthetic wakefulness-promoting agent and is the single R-enantiomer of the racemic compound modafinil. It is chemically classified as a benzhydrylsulfinylacetamide derivative. Armoda is used clinically to improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. It is administered orally, typically once daily, and has a longer plasma half-life than modafinil, allowing more sustained plasma concentrations throughout the day.

Armoda belongs to the therapeutic class of wakefulness-promoting agents / CNS stimulants (non-amphetamine type). It is pharmacologically related to modafinil.

The precise mechanism by which Armodafinil promotes wakefulness is not fully established. It is known to act as an indirect dopamine receptor agonist: Armodafinil binds to the dopamine transporter (DAT) and inhibits dopamine reuptake, increasing extracellular dopamine levels in the brain, particularly in wake-promoting regions such as the hypothalamus. It also affects other neurotransmitter systems (e.g., norepinephrine, histamine, orexin) to a lesser extent. Unlike classic amphetamine-type stimulants, Armodafinil does not cause the same magnitude of widespread CNS stimulation, though it shares some sympathomimetic-like properties.

Pharmacokinetics

• Absorption: Well absorbed orally; peak plasma concentration reached in about 2 hours (may be delayed with food, though total absorption is largely unaffected).
• Metabolism: Extensively metabolized in the liver, mainly via CYP3A4/5, with some involvement of CYP2C19 and other enzymes.
• Elimination half-life: Approximately 15 hours.
• Excretion: Primarily via urine as metabolites, with minimal unchanged drug excreted.

Armoda is administered orally, once daily, with or without food. Tablets should be swallowed whole and taken at a consistent time relevant to the indication (morning for narcolepsy/OSA; approximately 1 hour before shift start for shift work disorder).

Armoda is a moderate inducer of CYP3A4 and may also affect CYP2C19-mediated metabolism, leading to several clinically significant interactions:

• Hormonal contraceptives: Armoda can reduce the effectiveness of hormonal contraceptives (including oral, implantable, and injectable forms) via CYP3A4 induction. Patients should use an alternative or additional non-hormonal method of contraception during treatment and for one month after discontinuation.
• CYP3A4 substrates (e.g., cyclosporine, certain steroidal contraceptives, midazolam-type drugs): Armoda may reduce their plasma concentrations, potentially reducing efficacy.
• CYP2C19 substrates (e.g., phenytoin, diazepam, propranolol, some tricyclic antidepressants): Armoda may inhibit their metabolism, increasing plasma concentrations and risk of toxicity; dose adjustment or monitoring may be needed.
• Warfarin: Concomitant use may alter warfarin metabolism; International Normalized Ratio (INR) should be monitored, especially when starting or stopping Armoda.
• CNS-active drugs/alcohol: Use with other stimulants or CNS depressants (including alcohol) should be approached with caution due to potential additive effects on the central nervous system.
• Monoamine oxidase inhibitors (MAOIs): Caution is advised due to theoretical risk of increased blood pressure; clinical experience with concurrent MAOI use is limited.

Patients should inform their physician of all medications, including hormonal contraceptives, before starting Armoda.

The most common side effects of Armoda include:

• Headache
• Nausea
• Dizziness
• Insomnia / difficulty sleeping
• Anxiety
• Dry mouth

Serious Side Effects (seek medical attention promptly)

• Serious skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) - rare but potentially life-threatening; discontinue Armoda at the first sign of rash, hives, or mucosal lesions.
• Hypersensitivity reactions including angioedema and anaphylaxis.
• Psychiatric symptoms: anxiety, agitation, mania, hallucinations, suicidal ideation, or aggression, more common in patients with a prior psychiatric history.
• Cardiovascular effects: increases in blood pressure and heart rate; chest pain, palpitations, or arrhythmia in susceptible individuals.

Pregnancy: Armoda should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Animal reproduction studies have shown adverse developmental effects at clinically relevant exposures, and human data are limited. Women who become pregnant while taking Armoda are encouraged to enroll in the manufacturer's pregnancy registry, and should consult their physician promptly.

Lactation: It is not known whether Armoda or its metabolites are excreted in human breast milk. Because many drugs are excreted in breast milk and the effects on a nursing infant are unknown, Armoda should be used during breastfeeding only after consulting a physician, weighing the benefits of treatment against potential risk to the infant.

Use Armoda with caution and under medical supervision in the following situations:

• History of psychiatric illness (depression, anxiety, mania, psychosis): Armoda may exacerbate psychiatric symptoms; discontinue if new or worsening symptoms occur.
• Cardiovascular disease: Armoda can cause modest increases in blood pressure and heart rate. Use caution in patients with left ventricular hypertrophy, mitral valve prolapse with prior CNS stimulant-associated arrhythmia, recent myocardial infarction, or unstable angina; blood pressure and heart rate should be monitored.
• Serious skin/hypersensitivity reactions: discontinue immediately if rash, blistering, mucosal involvement, or signs of anaphylaxis/angioedema occur (see Side Effects).
• Hormonal contraceptive use: Armoda may reduce contraceptive effectiveness; advise additional or alternative contraception (see Interactions).
• Does not replace primary therapy: in obstructive sleep apnea, Armoda improves wakefulness but does not treat the underlying airway obstruction; patients should continue CPAP or other prescribed primary treatment even if they feel more alert.
• Potential for dependence/misuse: although lower than with traditional stimulants, some potential for psychological dependence or misuse exists; use only as prescribed and avoid abrupt dose escalation.
• Hepatic impairment: dose reduction is recommended in severe hepatic impairment (see Dosage and Administration).
• Activities requiring alertness: Armoda improves wakefulness but does not eliminate the need for adequate sleep; patients should not assume normal alertness for driving or operating machinery until individual response is known.

Overdose with Armoda may cause insomnia, agitation, anxiety, confusion, tremor, palpitations, tachycardia, hypertension, nausea, and, in severe cases, seizures or cardiac arrhythmia. There is no specific antidote for Armoda overdose. In case of suspected overdose, seek immediate medical attention or contact a poison control center / emergency services. Management is supportive, with monitoring of cardiovascular status and general medical supportive care under hospital supervision; hemodialysis has not been established to significantly enhance elimination.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: The safety and efficacy of Armoda have not been established in patients younger than 17 years of age; Armoda is not recommended for use in children.

Elderly: Clinical studies have not identified specific age-related differences in response, but elderly patients may have reduced hepatic or renal clearance; dose adjustment and closer monitoring may be warranted, particularly for cardiovascular effects.

Hepatic impairment: Dose reduction recommended in severe hepatic impairment (see Dosage and Administration).

Renal impairment: No formal dose adjustment established; use with caution in severe renal impairment.

Pregnancy and lactation: See Pregnancy and Lactation section.

Duration of treatment with Armoda depends on the underlying condition and clinical response. Narcolepsy and obstructive sleep apnea generally require long-term, ongoing therapy under physician supervision, with periodic reassessment of continued need and benefit. Shift work disorder treatment is typically used for as long as the shift-work schedule persists. Treatment should not be continued longer than needed and should be periodically reviewed by the prescribing physician.

Armodafinil belongs to the drug class of wakefulness-promoting agents (eugeroics) / non-amphetamine CNS stimulants, and is the R-enantiomer of modafinil.

Armodafinil promotes wakefulness primarily by acting as an indirect dopamine receptor agonist: it binds the dopamine transporter and inhibits dopamine reuptake, increasing extracellular dopamine in wake-promoting brain regions such as the hypothalamus. The precise mechanism underlying its wake-promoting effect has not been fully elucidated, though it may also modestly affect norepinephrine, histamine, and orexin signaling pathways involved in the sleep-wake cycle.

C

The safety and efficacy of Armoda have not been established in pediatric patients (under 17 years of age). Armoda is therefore not recommended for use in children or adolescents. In clinical trials of the related compound modafinil in pediatric patients, serious skin rash (including cases requiring hospitalization) was observed, contributing to caution against pediatric use of this drug class. Any pediatric use of Armoda should only occur under specialist supervision if considered essential, with close monitoring for dermatologic and psychiatric adverse effects.